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Abstract
Background: Several secondary metabolites from
herbal nutrient products act as weak estrogens
(phytoestrogens), competing with endogenous
estrogen for binding to the estrogen receptors and
inhibiting steroid converting enzymes. However, it is
still unclear whether these compounds elicit estrogen
dependent transcription of genes at physiological
concentrations. Methods: We compare the effects of
physiological concentrations (100 nM) of the two
phytoestrogens Enterolactone and Quercetin and the
suspected phytoestrogen Curcumin on gene
expression in the breast cancer cell line MCF7 with
the effects elicited by 17-β-estradiol (E2). Results: All
three phytocompounds have weak effects on gene
transcription; most of the E2 genes respond to the
phytoestrogens in the same direction though to a
much lesser extent and in the order Curcumin >
Quercetin > Enterolactone. Gene regulation induced
by these compounds was low for genes strongly
induced by E2 and similar to the latter for genes only
weakly regulated by the classic estrogen. Of interest
with regard to the treatment of menopausal symptoms,
the survival factor Birc5/survivin and the oncogene
MYBL1 are strongly induced by E2 but only marginally
by phytoestrogens. Conclusion: This approach
demonstrates estrogenic effects of putative
phytoestrogens at physiological concentrations and
shows, for the first time, estrogenic effects of
Curcumin.
Introduction
Many breast cancer risk factors are related to
cumulative exposure to estrogens [1] including hormone
replacement therapy [2, 3]. Contact to environmental
pollutants with estrogenic activity has also been associated
with a slightly elevated breast cancer risk [4] and
geographical or apparently ethnic differences in breast
cancer incidence have been attributed to diets containing
natural compounds with weak estrogenic activity called
phytoestrogens [5].
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Phytoestrogens are plant derived substances that
have estrogenic activity. They bind to the estrogen
receptor with an affinity 1000-10000 fold lower than that
of the endogenous hormone and initiate estrogen-
dependent transcription [6]. According to their chemical
structures phytoestrogens are classified into six main
groups: flavones, flavonones, isoflavones, coumestans,
lignans, and stilbenes.
Phytoestrogens have been proposed for
chemoprevention and as a substitute of hormone
replacement therapy [5], because it can be assumed that
they compete with the endogenous hormone for binding
to the estrogen receptor, thereby reducing the proliferative
effects of endogenous estrogens. However, in the
absence of endogenous hormone, phytoestrogens could
stimulate proliferation of breast cancer cells and contribute
to breast cancer progression. Hence, the question of
whether phytoestrogens are safe substitutes of hormone
replacement therapy is still open.
In addition to receptor dependent functions there is
growing evidence that phytoestrogens reduce local
production of estrogens by inhibiting the activity of key
steroidogenic enzymes involved in the synthesis of
estradiol (E2) [7, 8]. Phytoestrogens could diminish local
estrogen levels by inhibiting their converting enzymes
thereby reducing the proliferation stimulus and thus
protect against breast cancer progression.
The estrogenicity of a compound is reflected by its
effect on the growth of estrogen-responsive breast cancer
cells that can be measured in vitro by a series of assays
[9, 10]. Growth-promoting effects have been observed
for genistein and other isoflavones such as daidzein and
biochanin A [11] only at low doses (= 10 µM) in ER-
positive MCF7 and T47D cells whereas at higher doses,
growth and survival of both ER-positive and ER-negative
(MDA-MB-231 and -435) cells were inhibited [12-20].
The flavones quercetin and apigenin inhibit E2-induced
DNA synthesis and proliferation of ER-positive and ER-
negative breast cancer cells [21-23]. Lignans have also
been investigated for their effects on cell growth. At low
doses enterolactone stimulated but at concentrations
above 10 µM, it inhibited proliferation of MCF7 cells [24,
25].
Hormone replacement therapy (HRT) is usually
prescribed to reduce the incidence of cardiovascular and
coronary heart diseases or bone fractures in post-
menopausal women. In 2002, the initial results of a long-
term randomized controlled trial of HRT (Women’s Health
Initiative [WHI]) showed that, after 5 years of combined
estrogen and progestogen therapy in an older population,
there was a significant reduction in fractures, no overall
cardiovascular benefit, and an increased rate of breast
cancer [3]. The increased cancer risk appears to dissipate
after ending HRT [26]; this has caused a decrease of the
use of HRT in the United States which in turn has
contributed to a decline of breast cancer incidence [27].
New approaches for treatment of menopausal symptoms
are therefore highly desirable. Natural plant-derived
phytoestrogens show a weak estrogenicity and could
therefore be an alternative to HRT although it is not clear
whether they are efficacious and safe.
Here we addressed phytoestrogen effects on gene
transcription using complex microarrays in order to
establish i) whether estrogenic effects can be observed
at a physiological concentration, ii) whether eventual
estrogenic effects are generalized to all estrogen
responsive genes and iii) whether the extent of regulation
is similar for all estrogen responsive genes. We tested
three molecules belonging to three different classes of
plant derived secondary metabolites: Curcumin is a
polyphenol [28] derived from the plant curcuma longa
used as a spice component (curry), Enterolactone is a
lignan present in flax and sesame seeds and in many
vegetables and berries [29] and Quercetin is a flavonoid
present in apples, in tea, in grapes and in many vegetables
[30]. Quercetin and Enterolactone but not Curcumin are
known phytoestrogens. However it is already known that
this polyphenol is able to displace > 85% of estradiol
binding to its receptor as shown by 3H-estradiol ligand
binding assays [31].
Many in vitro studies have been performed with
rather high phytoestrogen concentrations (10 µM and
above) that are unlikely to be achieved in vivo and it is
not clear whether the effects on gene transcription
observed under these conditions have any clinical
relevance. For this reason we decided to use a
concentration of 100 nM that has been measured in the
breast cyst fluid of untreated women [32].
We show, through the correlation with an estrogen
reference gene expression profile, that the phytoestrogens,
including Curcumin, have estrogenic effects on gene
transcription even at low, physiological concentrations.
Materials and Methods
Cell culture and treatment
MCF7 cells were obtained from ICLC cell line collection
(Genoa, Italy) and grown at 37 °C in a humidified atmosphere of
5 % CO2 in DME medium supplemented with 10 % fetal calf
serum and 1 % L-glutamine solution (200 mM). Medium was
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changed every two days. Before the start of the experiments,
cell cultures were kept for 10 days in phenol red free DMEM
(Seromed, Berlin, Germany) supplemented with 10 % dextran
coated charcoal treated fetal calf serum (Seromed, Berlin,
Germany). In this period, medium was changed each other day
and cell cultures were rinsed three times with PBS. Cells were
treated for 72 h with 1nM 17-β-estradiol (E2), 100 nM Curcumin,
100 nM enterolactone or 100 nM quercetin (all from Sigma, St.
Louis, USA) in ethanol (stock concentration = 100 µM) or with
vehicle alone (control).
Preparation of RNA and cRNA
Total RNA was isolated using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. cDNA synthesis was performed using T7-(dT)24
oligo primers and the Custom SuperScript Double-Stranded
cDNA Synthesis Kit (Invitrogen, Irvine, CA, USA). Double
stranded cDNAs were extracted with phenol-chloroform-
isoamyl alcohol (25:24:1), ethanol precipitated, and used to
prepare cRNAs using the Bioarray High Yield RNA
Transcription Kit (Affymetrix, Santa Clara, CA, USA) according
to the manufacturer’s instructions. cRNAs were purified using
the RNeasy Mini Kit (Qiagen, Hilden, Germany), controlled by
agarose gel electrophoresis and subjected to fragmentation
for 35 min. at 94 °C in fragmentation buffer (40 mM Tris-acetate
pH 8.1, 100 mM CH3COOH, 30 mM Mg(CH3COO)2x4H2O).
GeneChip microarray analysis and data normalization
Labeled cRNA was used for screenings of GeneChip Human
Genome U133plus2 arrays (Affymetrix, Santa Clara, CA, USA).
The experiment consisted of 3 biological replicates.
Hybridization and scanning was performed on the Affymetrix
platform. Data were normalized following the GCRMA procedure
[33] of Bioconductor 2.3.1 [34] (http://www.bioconductor.org).
Statistically significant expression changes were determined
using permutation tests (SAM, [35] (http://www-
stat.stanford.edu/~tibs/SAM/). Genes regulated at least two
fold in comparison to untreated controls were considered. The
delta value was set to return a median false significant number
of zero. Annotations were obtained through the DAVID
database (http://david.niaid.nih.gov/david/beta/index.htm) [36].
Reference profile correlation
Gene expression profiles of phytoestrogen treated cells
were compared to 17-β-estradiol treated cells. For this purpose,
significantly E2-regulated genes (E2 responsive genes) were
identified through class comparison using SAM as described
above. Expression values of E2 responsive genes in E2 and
phytoestrogen treated cells were analyzed by Spearman
correlation and plotted. P and r-values were calculated. Since
Spearman correlation is non-parametric no r2-values were
available.
Quantitative RT-PCR
Expression data validation was performed by quantita-
tive real-time RT-PCR using the RNA extracted from drug- or
mock-treated cells as described previously. Expression data
were normalized on GAPDH and on RNA polymerase II (RPII)
gene expression data obtained in parallel. Expression changes
were calculated using the mean value of normalizations ob-
tained using GAPDH and RPII genes as house keeping genes.
Preparation of Cellular Extracts
Cells were washed 3 times with PBS and collected by
scraping and centrifuged. Lysis buffer (10 mM Na3PO4; 0.4M
NaCl; 0.2 % Triton X-100) was added to the pellets and the
mixture was sonicated. After centrifugation for 15 min at 15000xg
the supernatant containing the soluble proteins was collected
and either analyzed immediately or stored at -20 °C.
Protein Determination
Protein concentrations were determined by the BCA pro-
tein assay (Pierce, Oud-Beijerland, Netherlands) with bovine
serum albumin as the standard.
Western Blots
Lysates from human MCF7 breast cancer cells treated
with 1nM E2 or different concentrations of Curcumin (100 nM,
1 µM, 10 µM and 25 µM) and non-treated control cells were
analyzed using an antibody against MYBL1 (Sigma
Deisenhofen, Germany). Equal amounts of protein were sub-
jected to SDS-PAGE and the intracellular amount of β-actin
was analyzed as loading control (antibody from Sigma
Deisenhofen, Germany). Additionally, the amount of protein
blotted onto the membranes was visualized with Ponceau red
before blocking. Following electrophoretic separation by so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis, pro-
teins were electro-blotted on nitrocellulose membranes
(Whatman, Brentford, UK). The membranes were blocked in 5
% non-fat milk (Merck, Darmstadt, Germany) overnight at 4 °C.
The first antibody was incubated for 1 h at room temperature.
Thereafter, membranes were washed in tris buffered saline with
Tween buffer, and a further incubation was carried out with a
peroxidase-conjugated antibody (Dako, Hamburg, Germany)
for 1 h at room temperature. The enhanced chemiluminescence
system was used for visualization of the protein bands as rec-
ommended by the manufacturer (GE Healthcare, Little Chalfont,
UK). Semi-quantitative evaluation of the bands was performed
by densitometric analysis with the ImageJ software provided
by the NIH (http://rsb.info.nih.gov/ij/).
Results
Estrogen Response Reference Profile in the
human breast cancer cell line MCF7
As a first step we generated a gene expression profile
of the estrogen receptor positive breast cancer cell line
MCF7. We used a concentration of 1 nM that is
considered to correspond to physiological levels and is
used in most in vitro studies. The choice of the time point
of 72 hours was based on the consideration that post-
menopausal women, the likely users of phytoestrogens,
have a relatively stable, non ovarian endogenous estrogen
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Table 1. Estrogen response reference
profile (E2 genes). Gene expression of
MCF7 cells after 72 hours of treatment
with 1nM 17-β-estradiol was analyzed by
microarray hybridization. Normalized ex-
pression data were analyzed by Signifi-
cance Analysis of Microarray (SAM).
The 25 most up- and down-regulated
genes that are statistically significantly
(false discovery rate (FDR) = 0%) regu-
lated by 17-β-estradiol are listed, expres-
sion values are given as fold change.
production and therefore, effects of a long term estrogen
exposure are more relevant. On the other hand, estrogens
strongly induce proliferation in MCF7 cells and very long
exposures would provoke cell density dependent
differences between E2 treated and control cells. At 72
hours, the immediate proliferative burst induced by
estrogen stimulation has faded out and a stable
proliferation rate has been reached. Gene expression was
assessed by microarray hybridization, in order to identify
genes that respond to the treatment with 17-β-estradiol.
We compared profiles obtained from E2 treated MCF7
cells with those from untreated cells. We performed a
significance analysis of microarrays using the permutation
test, SAM, that yielded 334 significantly (false discovery
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rate = 0 %) regulated probesets corresponding to 262
genes for 17-β-estradiol consistent with the known strong
effects of the steroid on estrogen receptor α expressing
cells. Most of these genes have been described to be
regulated by estrogen. Table 1 shows the expression
values relative to untreated control cells for estradiol. In
the following we refer to this list as the estrogen response
reference profile (E2 genes). The validation of the
estrogen response of several of these genes by real time
PCR yielded fully concordant data (data not shown).
Expression analyses after treatment with
phytoestrogens
In parallel we treated MCF7 cells with the
phytoestrogens Quercetin and Enterolactone and the
suspected phytoestrogen, Curcumin, for 72 hours. The
phytoestrogen concentration of 100nM corresponds to
the maximal concentration observed for Enterolactone in
breast cyst fluid [32] that is two orders of magnitude lower
than the concentrations used in most in vitro studies of
phytoestrogens. Applying the same statistical approach
to the comparison of each single phytoestrogen and the
control profile, no significant gene regulation events could
be identified. The effects of Curcumin on gene expression
in MCF7 cells are shown in Table 2 and presented as
fold change over control cells.
Reference profile correlation
We noticed that many genes that were regulated by
E2 more than twofold in a statistically significant manner
were regulated in the same direction yet to a much lesser
extent by Curcumin (Fig. 1A). Viceversa, most Curcumin
regulated genes are regulated in the same direction by
E2 (Fig. 1B). Genes regulated by Quercetin and
Enterolactone also showed this tendency (data not shown).
87 %, 50 % and 79 % of the E2 genes were
regulated in the same direction by Curcumin,
Enterolactone and Quercetin, respectively, and the mean
extent of regulation was about one tenth of that observed
for estradiol (Table 3). The expression change of these
Table 2. Effects of 100
nM Curcumin on gene
expression in MCF7 cells.
Gene expression of MCF7
cells after 72 hours of
treatment with 100nM of
Curcumin was analyzed by
microarray hybridization.
Fold change values as
compared to untreated
controls are shown for and
Curcumin (FC_CUR) and
estradiol (FC_E2). All
genes with a p-value
(Curcumin versus control,
student´s T-Test) < 0.05
and a fold change value
>1.5 are shown.
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genes after phytoestrogen treatment is low and on
its own not statistically significant. We therefore wished
to know whether there is a significant correlation
between the effects of 17-β-estradiol and phytoestrogens,
independent of the extent of regulation. We performed
Spearman correlation analyses on the expression
data limited to the E2 genes. These correlations
were significant for all three phytoestrogens in the
order of Curcumin (r=0.3941, p<0.0001) > Quercetin
Fig. 1. Expression of Curcumin
responsive genes in 17-β-
estradiol treated cells. Gene
expression of MCF7 cells after
72 hours of treatment with 1 nM
E2 or 100 nM Curcumin was
analyzed by microarray
hybridization. Expression values
obtained form Curcumin (black
bars) and 17-β-estradiol (grey
bars) treated cells are shown for
all estradiol responsive genes
(panel A) and for all Curcumin
responsive genes (panel B).
Expression values are indicated
as Log2 ratios over untreated
controls (1 = two fold induction,
-1 = twofold decrease).
Table 3. Regulation of estradiol responsive genes by
Curcumin, Quercetin and Enterolactone.
Fig. 2. Reference profile correlation. Spearman correlation of expression values obtained for E2 genes after treatment with 1nM
17-β-estradiol (abscissas) with those obtained after treatment with 100 nM of Curcumin, Quercetin or Enterolactone (ordinates)
as indicated. Values are shown in log2 scale. Most of the genes are in the first and third quadrants that contain genes regulated
in the same direction by the two compounds. This correlation is strongest for Curcumin and weak for Enterolactone.
Bachmeier/Mirisola/Romeo/Generoso/Esposito/Dell’Eva/Blengio/
Killian/Albini/Pfeffer
Cell Physiol Biochem 2010;26:471-482
477
(0.3105, p<0.0001) > Enterolactone (r=0.1377,
p=0.0118) (Fig. 2).
Fig. 3. Real time PCR and Western Blot validation of Curcumin
effects on estrogen responsive genes. (A) Expression data are
indicated as log2 of the expression values normalized on the
expression values of three housekeeping genes analyzed in
parallel (G6PD, GAPDH and RPII). E2 indicates expression
values in 17-β-estradiol treated cells (positive control). (B)
Expression of MYBL1 (upper panel) was analyzed on protein
level by Western Blots of lysates from E2 and Curcumin treated
MCF7 cells in comparison to un-treated cells. Lanes 1: un-
treated cells, lanes 2: cells treated with 1nM E2; lanes 3: cells
treated with 100 nM Curcumin, lanes 4: cells treated with 1 µM
Curcumin, lanes 5: cells treated with 10 µM Curcumin, lanes 6:
cells treated with 25 µM Curcumin. Expression levels were
normalized to β-actin (lower panel) by densitometric analysis
(middle).
Validation of gene expression by real time PCR
and Western Blot
Since Curcumin yielded the most significant
estrogen-like effects although it had not yet been classified
as a phytoestrogen we validated the effect on gene
expression by quantitative RT-PCR. We assumed that
the phytoestrogenic effect of Curcumin would be more
pronounced at higher concentrations. We tested
concentrations of 100 nM to 25 µM (25 µM is the
concentration used in most in vitro studies of Curcumin).
We selected a small series of genes with different
fold change values (maximum: CXCL12, 281 fold induced,
minimum: IL17RB, 8 fold induced) after E2 treatment
from the list of E2 genes (Table 1) for validation. In the
selection we did not consider the extent of regulation by
Curcumin. Fig. 3A shows that all of the eight estrogen
regulated genes tested are also up-regulated by Curcumin
in a dose dependent manner. BRCA2 and CXCL12
appear slightly downregulated by Curcumin at the lowest
concentration (100 nM) but clearly upregulated by the
higher concentrations. SGK shows a biphasic behavior.
It is most likely that the reproducibility between
microarray data and RT-PCR data drops at low
concentrations since the extent of regulation is very limited
and hidden by the intrinsic variability of the measurements.
Thus, the reference profile correlation approach can
identify estrogenic effects despite the intrinsic noise of
the data.
In order to verify Curcumin effects at protein level,
we have added Western blot analysis of one of the most
strongly Curcumin modulated genes, MYBL1. Our results
from protein analysis confirm the gene expression data
although Curcumin at higher concentrations shows the
opposite effect, which we attribute to its known anti-
proliferative and pro-apoptotic functions at higher
concentrations (Fig. 3B). Although the effect of Curcumin
at a concentration of 100nM on the regulation of estradiol
induced genes is only tiny, this effect is significant if one
compares the estrogen effects with those elicited by
Curcumin on all estradiol-regulated genes.
Differential effects of the phytoestrogens on E2
genes
As expected, the effects of 17-β-estradiol were
much stronger although the steroid was used at a
concentration 100 fold lower than that used for the
phytoestrogens. However, the ratio of the fold change
values for 17-β-estradiol versus control in comparison to
that of the phytoestrogens versus control is not the same
for all the genes analyzed. Apparently, strongly estradiol-
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induced genes respond to a lesser extent to the three
phytoestrogens tested whereas only weakly estrogen
responsive genes are affected to a similar extent by the
herbal analogs. The ten genes that are most strongly
upregulated by E2 are on average 103 fold more induced
by E2 as compared to Curcumin whereas the ten most
weakly E2 upregulated genes are only 2 fold increased
by E2 as compared to the polyphenol. We wished to know
whether there is a specific relation between the extent of
responsiveness to 17-β-estradiol and to the
phytoestrogens. In Fig. 4, the ratios between the fold
changes (17-β-estradiol versus control divided by
phytoestrogen versus control) are plotted over the 17-β-
estradiol fold change values. It becomes clear that there
is an almost perfect linear correlation for all three
phytoestrogens. The power of the phytoestrogens was
low for genes strongly regulated by 17-β-estradiol and
similar to the latter for genes only weakly regulated by
the classic estrogen. The linear correlation is determined
by the fact that the phytoestrogens have quantitative
similar effects on all genes whereas E2 has drastically
different effects on these genes.
Functional analysis of phytoestrogen induced
genes
The ideal molecule for hormone replacement therapy
would maintain the protective effects that estrogens exert
on bones, the cardiovascular system and the brain but
not the cancer promoting effects on proliferation and
apoptosis. We showed that the phytoestrogens tested exert
Table 4. Analysis of enrichment of gene annotation categories.
Gene ontology categories of the 50 genes with the highest and
the lowest ratio of induction by E2 versus Curcumin were
compared with those of the E2 genes in order to identify
functional gene classes that are significantly over-represented
in these two subgroups of differential (phyto)estrogen
responsiveness as compared to all estrogen responsive genes.
Hits with p<0.05 are shown. MCM complex is defined as a
hexameric protein complex required for the initiation and
regulation of DNA replication.
Fig. 4. Correlations between the regulation extents. Analysis of the correlation between the extent of responsiveness to 17-β-
estradiol (fold E2, ordinates) and the ratio between the extent of responsiveness to 17-β-estradiol and responsiveness to the
phytoestrogens (fold E2/CU, E2/QC, E2/EL, abscissas).
bland estrogenic effects on most E2 genes yet to various
extents as compared to E2. We therefore asked whether
these differences affect genes with different functions.
For this purpose we analyzed which functional categories
of genes (Gene Ontology) are enriched among the 50
genes with the highest difference in induction between
17-β-estradiol and Curcumin treated cells in comparison
to the whole list of genes that are regulated in the same
direction by the two compounds and then repeated the
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analysis for the genes with the lowest difference (upper
50 and lower 50, Table 4) using DAVID annotation tools.
The analysis revealed a significant enrichment of signal
peptide encoding genes among the fifty genes with the
highest difference and minichromosome maintainance
genes among the lower fifty genes. It is therefore
conceivable that the estrogenic effect of Curcumin is less
pronounced on estrogen induced protein secretion. In fact,
the inflammatory chemokine CXCL12 is the most
differentially regulated gene in the list. However,
Curcumin apparently maintains estrogenic activity on the
initiation of replication where MCM proteins are required.
Among the upper 50 genes we also detected the
oncogenic transcription factors v-MYB and a member
of the E2F family (E2F7) as well as the survival factor
BIRC5/survivin but also the tumor suppressor BRCA2.
In addition to the MCM genes other replication related
genes such as flap-structure specific endonclease, FEN1,
and DNA-topoisomerase 2a, TOP2A, are found among
the lower 50 genes.
Discussion
Here we analyze the effects on gene expression
exerted by two putative estrogenic substances isolated
from plants, Quercetin and Enterolactone, that have been
proposed as substitutes for hormone replacement therapy
(for a review see [5]) plus the polyphenol Curcumin,
which is suspected to exert estrogenic activity. Such
phytoestrogens are of major interest especially since
hormone replacement therapy has been reported to
increase breast cancer risk [3, 37]. Identification of
compounds that have the beneficial effects of estrogens
on bone and cardiovascular homeostasis and that can
reduce the menopausal symptoms is an active area of
research. Substitutes for classic hormone replacement
therapy might also increase breast cancer risk through
the activation of estrogen signaling. Phytoestrogens that
are proposed as such substitutes must therefore
thoroughly be characterized with regard to their estrogenic
effects. On the other hand, for many of the proposed
compounds, conclusive evidence of their estrogenic
activity and methods to quantify the “estrogenicity” are
still missing.
In order to identify the potentially estrogenic effects
of Enterolactone, Quercetin and Curcumin in breast
cancer cells we analyzed in a first approach all genes
that are regulated by 17-β-estradiol (E2). If a compound
has estrogen-like activities it is expected to mimic estrogen
effects on gene transcription though the effect will be
much weaker. The range of the expression change that
we observed in response to E2 in the human estrogen-
sensitive breast cancer cell line MCF7 ranges from 2
fold to 281 fold. It is as yet unknown how these drastically
different effects are obtained. Transcription factor binding
sites, the long and short range chromatin structure, the
actual sequence, possible cytosine methylation and the
availability of transcriptional co-activators and -repressors
may contribute to the actual responsiveness of a gene
[38-40].
All three compounds tested at the physiological
concentration of 100 nM regulate many E2 genes in the
same direction like 17-β-estradiol yet the extent of
regulation is very limited. The comparison between
untreated controls and phytoestrogen treated cells does
not yield statistically significant gene regulation events.
However, the gene expression profile elicited by the
phytoestrogens shows a significant correlation with the
profile in response to 17-β-estradiol. Interestingly,
Curcumin showed the strongest effects and the most
significant correlation. Estrogenic effects of this compound
have been described [28] although polyphenols are usually
not considered as phytoestrogens.
Curcumin has been described to inhibit nuclear factor
kappa B (NFκB) activation [41] and we have recently
shown that this also holds true for breast cancer where
the polyphenol reduces the number of metastases formed
by estrogen receptor (ER) negative MDA-MB-231 cells
in a mouse model of hematogenous metastasis through
the inhibition of NFκB mediated expression of matrix
metalloproteinases and chemokines [42, 43].
The ER is able to trans-repress NFκB [44] and this
might interfere with the effects of Curcumin on NFκB
regulated but not E2 genes. On the other hand, trans-
repression of estrogen signaling by NFκB has also been
reported [45]. This is however unlikely to contribute to
the estrogenic effects of the polyphenol since NFκB
affects the ERβ that is not expressed or expressed at
very low levels in MCF7 cells. Hence, the activation of
E2 genes by Curcumin most probably constitutes an ERα
mediated estrogen-like effect.
When we compared the relation between the
responsiveness to E2 with that to the phytoestrogens we
observed that there is an intriguing relation: The stronger
a gene is regulated by estrogen the higher is the fold
difference between the estrogen effect over the
phytoestrogen effect. This correlation is linear. We would
have expected a nonlinear relation with the genes
belonging to distinct groups, as it would be the case if
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there was a correlation with the number of estrogen
responsive elements (EREs) present in the promoter. The
estrogen receptors homodimerize upon ligand binding [46]
and the hormone also induces a conformational change
in the receptor proteins that is needed for co-activators
to bind to the receptor-DNA complex [47]. Different
extents of gene activation by the ligand bound estrogen
receptors are likely due to different promoters being bound
by different receptor-co-activator combinations [38, 39].
The stronger the effect of estrogen the more it depends
on co-activators. If the phytoestrogens were unable to
recruit co-activators while inducing dimerization and
DNA-binding, their activity would correspond to the low,
co-activator independent activation obtained by the free
ER dimers. This would explain the linear dependence
between activation by E2 and the ratio between E2 and
the phytoestrogens.
The decision whether the phytoestrogens analyzed
might be safe substitutes for hormone replacement therapy
would be straightforward using our approach if the genes
with a presumed protective effect were in the group of
relative strong phytoestrogen effects and the genes with
presumed influence on the breast cancer risk were in the
opposite group where phytoestrogens yield only very weak
effects as compared to estradiol. The most frequent
functional classes of estrogen regulated genes are related
to cell proliferation. The analysis of annotation category
enrichment comparing genes were the difference between
the response to E2 and Curcumin is highest to those where
it is lowest does not yield conclusive evidence of
functional differences since several replication related
genes are similarly regulated by estradiol and Curcumin.
However, the anti-apoptotic gene BIRC5/survivin and
two oncogenic transcription factors are in the uppermost
quintile of genes strongly regulated by estradiol but weakly
responsive to phytoestrogens. These genes certainly
contribute to the breast cancer risk and as a matter of
fact, BIRC5/survivin and the MYBL1 homologue
MYBL2 are included in the recurrence score developed
by Paik and co-workers [48]. We have recently shown
that expression of the estrogen induced cytokine CXCL12
in human breast cancer strongly correlates with disease
free survival [49]. Induction of CXCL12 could therefore
be protective yet Curcumin only weakly induces the
chemokine.
Here we compared effects on gene expression
elicited by weakly active compounds with the values
obtained after treatment of cells with a strong lead
compound E2. The analysis is limited to those genes that
are statistically significantly regulated by the latter. This
approach allows correlations of gene expression changes
between the lead and test compounds even when the
effect of test compounds on gene expression is not strong
enough to yield statistically significant gene regulation
events. We feel that this approach may prove useful for
many other weak but potentially interesting compounds,
especially in the field of chemoprevention where long term
treatments with non toxic and often weakly effective
compounds is sought.
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